Cargando…
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391235/ https://www.ncbi.nlm.nih.gov/pubmed/32011959 http://dx.doi.org/10.18553/jmcp.2020.26.2.221 |
| _version_ | 1785082659428368384 |
|---|---|
| author | Tran, Phuong T. Diaby, Vakaramoko |
| author_facet | Tran, Phuong T. Diaby, Vakaramoko |
| author_sort | Tran, Phuong T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10391235 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103912352023-08-02 Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer Tran, Phuong T. Diaby, Vakaramoko J Manag Care Spec Pharm Letter Academy of Managed Care Pharmacy 2020-02 /pmc/articles/PMC10391235/ /pubmed/32011959 http://dx.doi.org/10.18553/jmcp.2020.26.2.221 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Letter Tran, Phuong T. Diaby, Vakaramoko Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title | Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title_full | Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title_fullStr | Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title_full_unstemmed | Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title_short | Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer |
| title_sort | cost-effectiveness analysis of adjuvant neratinib following trastuzumab in early-stage her2-positive breast cancer |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391235/ https://www.ncbi.nlm.nih.gov/pubmed/32011959 http://dx.doi.org/10.18553/jmcp.2020.26.2.221 |
| work_keys_str_mv | AT tranphuongt costeffectivenessanalysisofadjuvantneratinibfollowingtrastuzumabinearlystageher2positivebreastcancer AT diabyvakaramoko costeffectivenessanalysisofadjuvantneratinibfollowingtrastuzumabinearlystageher2positivebreastcancer |